Glenmark Pharmaceuticals revealed that it will be marketing generic Montelukast Sodium tablets in the United States from August next year after it received approval by the US Food and Drug Administration to provide the drugs for treating asthma and seasonal allergies.
Glenmark said that it will be manufacturing the tablets after Merck's patent expires in August next year.
The tablets are generic version of the Singulair tablets being sold by Merck with the 10mg strength tablets generating more than $3.2 billion in sales in the last 12 months.
The company also said that it has 73 products available in the US market. Furthermore, it also has over 40 abbreviated new drug applications (ANDAs) that have been submitted to the FDA for approval.